Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of OSA Treatment on BP in CKD
NCT05846490Phase 4Recruiting
- Sponsor
- Universidade de São Paulo
- Start
- Jan 2024
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (2 arms), sponsored by Universidade de São Paulo. Primary endpoint: Need to adjust antihypertensive medication to control systolic BP (<130mmHg) at 1 year. Started Jan 2024; status: recruiting.
Beyond the preview
Go deeper on NCT05846490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05846490.